Cancer immunotherapy based on recombinant Salmonella enterica serovar Typhimurium aroA strains secreting prostate-specific antigen and cholera toxin subunit B

Cancer Gene Therapy

Volumn 15, Issue 2, 2008, Pages 85-93

  Fensterle, J ^a,b   Bergmann, B ^a,c   Yone, C L R P ^a   Hotz, C ^a   Meyer, S R ^a   Spreng, S ^c,d   Goebel, W ^c   Rapp, U R ^a   Gentschev, I ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b Zentaris GmbH   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d Berna Biotech AG   (Switzerland)

Author keywords

Bacterial cancer vaccines; Cancer immunotherapy; Cholera toxin subunit B; Hemolysin (HlyA) secretion system (T1SS); Prostate specific antigen

Indexed keywords

CANCER VACCINE; CHOLERA TOXIN B SUBUNIT; PROSTATE SPECIFIC ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; ESCHERICHIA COLI; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SALMONELLA TYPHIMURIUM; SEROTYPE; TUMOR GROWTH; VIRUS RECOMBINANT; WESTERN BLOTTING;

ANIMALS; CANCER VACCINES; CHOLERA TOXIN; ESCHERICHIA COLI PROTEINS; FEMALE; HEMOLYSIN PROTEINS; HUMANS; IMMUNOTHERAPY, ACTIVE; MALE; MICE; MICE, INBRED DBA; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SALMONELLA TYPHIMURIUM; SALMONELLA VACCINES; TYPHOID-PARATYPHOID VACCINES; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; MUS; SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHIMURIUM;

EID: 38349037623     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7701109     Document Type: Article

References (51)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C et al. Cancer statistics, 2006. C A Cancer J Clin 2006; 56: 106-130.
2. Lilja H, Oldbring J, Rannevik G, Laurell CB. Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. J Clin Invest 1987; 80: 281-285.
3. Oakley N. Clinical implications of prostate-specific antigen (PSA). Curr Opin Urol 1998; 8: 401-406.
4. Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 2002; 109: 409-417.
5. Barrou B, Benoit G, Ouldkaci M, Cussenot O, Salcedo M, Agrawal S et al. Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA. Cancer Immunol Immunother 2004; 53: 453-460.
6. Perambakam S, Hallmeyer S, Reddy S, Mahmud N, Bressler L, DeChristopher P et al. Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide. Cancer Immunol Immunother 2006; 55: 1033-1042.
7. Arlen PM, Gulley JL, Parker C, Skarupa L, Pazdur M, Panicali D et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 2006; 12: 1260-1269.
8. Miller AM, Ozenci V, Kiessling R, Pisa P. Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer. J Immunother 2005; 28: 389-395.
9. Mabjeesh NJ, Zhong H, Simons JW. Gene therapy of prostate cancer: current and future directions. Endocr Relat Cancer 2002; 9: 115-139.
10. Paglia P, Medina E, Arioli I, Guzman CA, Colombo MP. Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella typhimurium, results in protective immunity against a murine fibrosarcoma. Blood 1998; 92: 3172-3176.
11. Zoller M, Christ O. Prophylactic tumor vaccination: comparison of effector mechanisms initiated by protein versus DNA vaccination. J Immunol 2001; 166: 3440-3450.
12. Luo Y, Zhou H, Mizutani M, Mizutani N, Reisfeld RA, Xiang R. Transcription factor Fos-related antigen 1 is an effective target for a breast cancer vaccine. Proc Natl Acad Sci USA 2003; 100: 8850-8855.
13. Xiang R, Mizutani N, Luo Y, Chiodoni C, Zhou H, Mizutani M et al. A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res 2005; 65: 553-561.
14. Zhao M, Yang M, Li XM, Jiang P, Baranov E, Li S et al. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc Natl Acad Sci USA 2005; 102: 755-760.
15. Holmgren J, Adamsson J, Anjuere F, Clemens J, Czerkinsky C, Eriksson K et al. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Immunol Lett 2005; 97: 181-188.
16. Lycke N. Targeted vaccine adjuvants based on modified cholera toxin. Curr Mol Med 2005; 5: 591-597.
17. Sadeghi H, Bregenholt S, Wegmann D, Petersen JS, Holmgren J, Lebens M. Genetic fusion of human insulin B-chain to the B-subunit of cholera toxin enhances in vitro antigen presentation and induction of bystander suppression in vivo. Immunology 2002; 106: 237-245.
18. Yuki Y, Byun Y, Fujita M, Izutani W, Suzuki T, Udaka S et al. Production of a recombinant hybrid molecule of cholera toxin-B-subunit and proteolipid-protein-peptide for the treatment of experimental encephalomyelitis. Biotechnol Bioeng 2001; 74: 62-69.
19. Arakawa T, Yu J, Chong DK, Hough J, Engen PC, Langridge WH. A plant-based cholera toxin B subunit-insulin fusion protein protects against the development of autoimmune diabetes. Nat Biotechnol 1998; 16: 934-938.
20. Gentschev I, Mollenkopf H, Sokolovic Z, Hess J, Kaufmann SH, Goebel W. Development of antigen-delivery systems, based on the Escherichia coli hemolysin secretion pathway. Gene 1996; 179: 133-140.
21. Hess J, Gentschev I, Miko D, Welzel M, Ladel C, Goebel W et al. Superior efficacy of secreted over somatic antigen display in recombinant Salmonella vaccine induced protection against listeriosis. Proc Natl Acad Sci USA 1996; 93: 1458-1463.
22. Ryan ET, Butterton JR, Zhang T, Baker MA, Stanley Jr SL, Calderwood SB. Oral immunization with attenuated vaccine strains of Vibrio cholerae expressing a dodecapeptide repeat of the serine-rich Entamoeba histolytica protein fused to the cholera toxin B subunit induces systemic and mucosal antiamebic and anti-V. cholerae antibody responses in mice. Infect Immun 1997; 65: 3118-3125.
23. Gomez-Duarte OG, Pasetti MF, Santiago A, Sztein MB, Hoffman SL, Levine MM. Expression, extracellular secretion, and immunogenicity of the Plasmodium falciparum sporozoite surface protein 2 in Salmonella vaccine strains. Infect Immun 2001; 69: 1192-1198.
24. Gentschev I, Dietrich G, Goebel W. The E. coli alphahemolysin secretion system and its use in vaccine development. Trends Microbiol 2002; 10: 39-45.
25. Li Y, Reichenstein K, Ullrich R, Danner T, von Specht BU, Hahn HP. Effect of in situ expression of human interleukin-6 on antibody responses against Salmonella typhimurium antigens. FEMS Immunol Med Microbiol 2003; 37: 135-145.
26. Gentschev I, Fensterle J, Schmidt A, Potapenko T, Troppmair J, Goebel W et al. Use of a recombinant Salmonella enterica serovar Typhimurium strain expressing C-Raf for protection against C-Raf induced lung adenoma in mice. BMC Cancer 2005; 5: 15.
27. Wei C, Willis RA, Tilton BR, Looney RJ, Lord EM, Barth RK et al. Tissue-specific expression of the human prostatespecific antigen gene in transgenic mice: implications for tolerance and immunotherapy. Proc Natl Acad Sci USA 1997; 94: 6369-6374.
28. Datsenko KA, Wanner BL. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci USA 2000; 97: 6640-6645.
29. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685.
30. Fensterle J, Schwartz V, Riedmiller H, Rapp UR. Animal models for DNA vaccination against prostate cancer using PSA encoding plasmids. Onkologie 2005; 28(Suppl 2): 52.
31. Fensterle J, Grode L, Hess J, Kaufmann SHE. Effective DNA vaccination against listeriosis by prime/boost inoculation with the gene gun. J Immunol 1999; 163: 4510-4518.
32. Gentschev I, Dietrich G, Mollenkopf HJ, Sokolovic Z, Hess J, Kaufmann SH et al. The Escherichia coli hemolysin secretion apparatus-a versatile antigen delivery system in attenuated Salmonella. Behring Inst Mitt 1997; 95: 103-113.
33. Gentschev I, Hess J, Goebel W. Change in the cellular localization of alkaline phosphatase by alteration of its carboxy-terminal sequence. Mol Gen Genet 1990; 222: 211-216.
34. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 2006; 24: 175-208.
35. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001; 411: 380-384.
36. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21: 137-148.
37. Cardenas L, Clements JD. Oral immunization using live attenuated Salmonella spp. as carriers of foreign antigens. Clin Microbiol Rev 1992; 5: 328-342.
38. Ryan RM, Green J, Lewis CE. Use of bacteria in anti-cancer therapies. Bioessays 2006; 28: 84-94.
39. Kirby AC, Yrlid U, Wick MJ. The innate immune response differs in primary and secondary Salmonella infection. J Immunol 2002; 169: 4450-4459.
40. Brigl M, Bry L, Kent SC, Gumperz JE, Brenner MB. Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat Immunol 2003; 4: 1230-1237.
41. Holtmeier W, Kabelitz D. Gammadelta T cells link innate and adaptive immune responses. Chem Immunol Allergy 2005; 86: 151-183.
42. Reisfeld RA, Niethammer AG, Luo Y, Xiang R. DNA vaccines suppress tumor growth and metastases by the induction of anti-angiogenesis. Immunol Rev 2004; 199: 181-190.
43. Vassaux G, Nitcheu J, Jezzard S, Lemoine NR. Bacterial gene therapy strategies. J Pathol 2006; 208: 290-298.
44. Nishikawa H, Sato E, Briones G, Chen LM, Matsuo M, Nagata Y et al. In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines. J Clin Invest 2006; 116: 1946-1954.
45. Panthel K, Meinel KM, Sevil Domenech VE, Geginat G, Linkemann K, Busch DH et al. Prophylactic anti-tumor immunity against a murine fibrosarcoma triggered by the Salmonella type III secretion system. Microbes Infect 2006; 8: 2539-2546.
46. Wick MJ. Living in the danger zone: innate immunity to Salmonella. Curr Opin Microbiol 2004; 7: 51-57.
47. Bumann D. Regulated antigen expression in live recombinant Salmonella enterica serovar Typhimurium strongly affects colonization capabilities and specific CD4(+)-T-cell responses. Infect Immun 2001; 69: 7493-7500.
48. Harakuni T, Sugawa H, Komesu A, Tadano M, Arakawa T. Heteropentameric cholera toxin B subunit chimeric molecules genetically fused to a vaccine antigen induce systemic and mucosal immune responses: a potential new strategy to target recombinant vaccine antigens to mucosal immune systems. Infect Immun 2005; 73: 5654-5665.
49. Gentschev I, Dietrich G, Spreng S, Neuhaus B, Maier E, Benz R et al. Use of the α-hemolysin secretion system of Escherichia coli for antigen delivery in the Salmonella typhi Ty21a vaccine strain. Int J Med Microbiol 2004; 294: 363-371.
50. Gentschev I, Spreng S, Sieber H, Ures J, Mollet F, Collioud A et al. Vivotif - a 'magic shield' for protection against typhoid fever and delivery of heterologous antigens. Chemotherapy 2007; 53: 177-180.
51. Levine MM, Ferreccio C, Black RE, Germanier R. Large-scale field trial of Ty21a live oral typhoid vaccine in entericcoated capsule formulation. Lancet 1987; 1: 1049-1052.